Results 51 to 60 of about 2,744,211 (203)
Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: Report of 2 cases
, 2014 Background Once-yearly zoledronic acid has been proven effective in the management of osteoporosis. Osteonecrosis of the jaws (ONJ) related to its use has not been reported since its approval in 2007.
江俊斌;李正喆;郭生興;王逸平;鄭景暉;鄭世榮 +1 more
core +1 more source
Frontiers in Pain ResearchObjectiveTo evaluate the safety, efficacy, and cost-effectiveness of combining Compound Kushen Injection (CKI) with zoledronic acid in the treatment of bone metastasis-induced cancer pain in malignant tumors.MethodsA comprehensive search of Chinese and ...
Xi Zhao +5 more
doaj +1 more source
Bone Health and Aging in Klinefelter Syndrome
Andrology, EarlyView.ABSTRACT Klinefelter syndrome (KS) is typically diagnosed in young adults, but advances in prenatal testing have led to its recognition at a much earlier age. Conversely, diagnosis in late adulthood remains uncommon, but still occurs. Independently from the age at diagnosis, KS individuals now receive more accurate and tailored care management than in ...
Filippo Vignali +4 more
wiley +1 more source
, 2022 Objective: The primary purpose of this study was to estimate the cost-effectiveness of sequential denosumab/zoledronic acid versus zoledronic acid monotherapy for postmenopausal osteoporotic women in China.Methods: We updated and utilized a previously ...
Lei Ke (217815) +6 more
core +1 more source
British Journal of Haematology, EarlyView.Summary Myeloma bone disease (MBD) affects ~90% of myeloma patients, causing pain and reduced quality of life. Current anti‐resorptive treatments retard further destruction but do not repair bone. As new myeloma therapies emerge, understanding their impact on MBD is crucial.
Rebecca E. Andrews +7 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Zoledronic acid infusion for prevention and treatment of osteoporosis
, 2010 John A SunyeczLaurel Highlands Ob/Gyn, Hopwood, Pennsylvania, USA and MenopauseRx, Inc., Uniontown, PA, USAAbstract: Osteoporotic fractures are associated with significant morbidity, reduced quality of life, increased mortality, and high health care ...
John Sunyecz, John A Sunyecz
core +1 more source
, 2022 Objective: The primary purpose of this study was to estimate the cost-effectiveness of sequential denosumab/zoledronic acid versus zoledronic acid monotherapy for postmenopausal osteoporotic women in China.Methods: We updated and utilized a previously ...
Lei Ke (217815) +6 more
core +1 more source
Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency
Clinical Endocrinology, EarlyView.ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh +4 more
wiley +1 more source
Journal of Bone Oncology, 2015 Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor ...
Hampig Raphael Kourie +5 more
doaj +1 more source